Metabolic derangements in diabetes and mechanisms of cell damage by hyperglycaemia

Absolute (T1DM) or relative (T2DM) insulin deficiency results in impaired postprandial glucose uptake by skeletal muscle, decreased glucose processing into glycogen, inadequate suppression of hepatic gluconeogenesis and lipolysis in adipose tissue (NEFA further interferes with glucose oxidation via the glucose–NEFA cycle). If the cell cannot efficiently down regulate insulin-independent glucose intake in hyperglycaemia it becomes overloaded, which has been convincingly shown for endothelial⁽Reference Gaudreault, Scriven and Moore^9, Reference Kaiser, Sasson, Feener, Boukobza-Vardi, Higashi, Moller, Davidheiser, Przybylski and King¹⁰⁾, mesangial⁽Reference Brosius and Heilig¹¹⁾ and renal tubular⁽Reference Linden, DeHaan, Zhang, Glowacka, Cox, Kelly and Rogers¹²⁾ cells, all of which are targets for vascular damage by hyperglycaemia in diabetes. In the case of endothelial cells the expression of some types of facilitative glucose transporters stay stable or are moderately down regulated by glucose (GLUT1), while others (GLUT2) are up regulated⁽Reference Gaudreault, Scriven and Moore^9, Reference Kaiser, Sasson, Feener, Boukobza-Vardi, Higashi, Moller, Davidheiser, Przybylski and King¹⁰⁾. Intracellularly, glucose is metabolised via glycolysis and the Krebs cycle, and the electron donors (NADH and FADH₂) generated then supply electrons for the electron transport chain in the mitochondria to be used to generate H⁺ membrane potential for the production of ATP via ATP synthase. Increased availability of glucose and glycolytic intermediates have been shown to provide substrates for several pathways that are believed to be largely responsible for the cell damage induced by hyperglycaemia⁽Reference Brownlee²⁾: polyol and hexosamine pathways; dicarbonyl production (mainly methylglyoxal by degradation of triosephosphates) and non-enzymic glycation (AGE); de novo synthesis of diacylglycerol with subsequent activation of protein kinase C isoforms. The overall effects of these abnormalities are changes in gene expression by activation of certain transcription factors (mainly NF-κB), post-translational modification of intra- and extracellular proteins (glycation), alteration of cellular signalling (by activation of kinases), endoplasmic reticulum stress leading to unfolded protein response, impairment of antioxidant capacity etc. (for details, see Brownlee⁽Reference Brownlee^2, Reference Brownlee¹³⁾).

Recently, a ‘unifying’ hypothesis was proposed that strengthens the role of mitochondrial ROS overproduction and subsequent DNA oxidative damage as a potent accelerator of these abnormalities (originally seen merely as a result of increased substrate availability because of allosteric inhibition and thus accumulation of glycolytic intermediates). Hyperglycaemia overloads the mitochondrial electron transport chain by increased availability of reducing equivalents (mainly on complex III) and a larger proportion of O₂ is then partly reduced with single electrons to superoxide⁽Reference Brownlee¹³⁾. Overexpression of manganese superoxide dismutase or uncoupling protein-1 abolishes hyperglycaemia-induced ROS generation in vitro ⁽Reference Nishikawa, Edelstein and Du¹⁴⁾. In fact, NADH:NAD⁺ rather than the absolute amount of NADH seems to be important for the intensity of mitochondrial superoxide generation⁽Reference Adam-Vizi and Chinopoulos¹⁵⁾, and since hyperglycaemia-induced ROS generation directly contributes to an increase in the NADH:NAD⁺ (see later), diabetes represents a vicious circle in relation to oxidative stress. ROS can oxidatively damage most types of macromolecules; however, oxidative damage of DNA (strand breaks) is particularly important since it requires energy-consuming repair. Ribosylation of multiple proteins by poly-ADP-ribose polymerase, including auto-ribosylation of poly-ADP-ribose polymerase, itself initiates and facilitates DNA repair⁽Reference Soriano, Virag and Szabo¹⁶⁾. NAD⁺ serves as a donor of ADP-ribose and its consumption by poly-ADP-ribose polymerase contributes to its decreased availability (an increase in NADH:NAD⁺), further ROS generation and a decrease in ATP formation. Pharmacological inhibition of poly-ADP-ribose polymerase in vitro can suppress all these abnormalities in streptozotocin-induced diabetes⁽Reference Soriano, Pacher, Mabley, Liaudet and Szabo¹⁷⁾. Depletion of NAD⁺ also inhibits the key glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and causes the accumulation of upstream glycolytic intermediates and their processing in alternative metabolic pathways (see earlier discussion, p. 61). Experimentally, GAPDH antisense oligonucleotides applied to cells cultured in 5 mm-glucose completely mimics hyperglycaemia by activating pathways leading to vascular damage to the same extent as in 30 mm-glucose culture conditions⁽Reference Du, Matsumura, Edelstein, Rossetti, Zsengeller, Szabo and Brownlee¹⁸⁾. GAPDH is generally viewed as a classical glycolytic enzyme; however, it is now clear that it is a multifunctional protein with diverse functions in numerous cellular processes including apoptosis and DNA repair⁽Reference Sirover¹⁹–Reference Chuang, Hough and Senatorov²¹⁾. GAPDH translocates to the nucleus under a variety of stressors, most of which are associated with oxidative stress. Interestingly, poly-ADP-ribosylation of GAPDH itself seems to be one of the likely events enabling its nuclear translocation (further slowing down the rate of glycolysis) and yet another factor responsible for the harmful effect of hyperglycaemia⁽Reference Du, Matsumura, Edelstein, Rossetti, Zsengeller, Szabo and Brownlee¹⁸⁾.

Formation of advanced glycation end products in vivo by non-enzymic glycation

Non-enzymic glycation (also termed the Maillard reaction in some contexts) of proteins involves interplay of serial and parallel reactions between protein residues (mainly lysine and arginine) and sugars, α-oxoaldehydes (dicarbonyls) and other sugar derivatives (in vivo mainly triosephosphate derivatives) generating early (pre-AGE) and advanced glycation products (AGE)⁽Reference Thornalley, Battah, Ahmed, Karachalias, Agalou, Babaei-Jadidi and Dawnay²²⁾. Glycation is one of the most common types of protein modification and spontaneous damage of proteins, which affects approximately 0·1–0·2% of the arginine and lysine residues in vivo ⁽Reference Thornalley, Battah, Ahmed, Karachalias, Agalou, Babaei-Jadidi and Dawnay²²⁾. Glycation of proteins proceeds with variable rate and extent during the lifespan of proteins in tissues and body fluids under physiological conditions, but it is more intensive in several disease conditions such as diabetes⁽Reference Vlassara and Palace²³⁾, atherosclerosis⁽Reference Baynes and Thorpe²⁴⁾, neurodegenerative diseases⁽Reference Munch, Deuther-Conrad and Gasic-Milenkovic²⁵⁾, osteoarthritis⁽Reference DeGroot²⁶⁾ and renal failure⁽Reference Thornalley²⁷⁾. The rate of reaction depends on variables such as temperature, pH and carbonyl:amine, and is thus topically and temporally variable. Generation of some AGE is substantially enhanced in the presence of ROS and some AGE are formed exclusively under oxidative conditions (hence the alternative term ‘glycoxidation’). Originally, glycation was considered to be a type of post-translational modification that occurs mostly in long-lived proteins (e.g. collagen, crystalline); however, it is now clear that AGE are formed also in short-lived proteins, including the cellular proteome⁽Reference Ahmed and Thornalley^4, Reference Thornalley, Battah, Ahmed, Karachalias, Agalou, Babaei-Jadidi and Dawnay²²⁾.

Glycating agents in vivo include free sugars (glucose), glycolytic intermediates such as sugar phosphates (glucose- and fructose-6-phosphates) and dicarbonyls (methylglyoxal, glyoxal and 3-deoxyglucosone). Sugars are reactive towards lysine residues while dicarbonyls are mainly reactive towards arginine residues of proteins. Glycation by sugars proceeds through the early (Schiff's bases) and intermediate stages (Schiff's bases undergo the Amadori rearrangement to fructosamines) towards the formation of heterogeneous moieties collectively termed AGE. If the initial glycating agent is glucose the initial product is termed a fructosamine. Probably the best-studied fructosamine to date is HbA_1c, which is glycated on the NH₂-terminal valine of the β-globin chain, although Hb can also be glycated on several other lysine residues. Since its discovery in 1968⁽Reference Rahbar²⁸⁾ HbA_1c has been established as a widely used and very useful marker of medium- to long-term compensation of diabetes with a certain predictive value⁽Reference Pickup, Pickup and Williams²⁹⁾. Quantitatively, however, fructoselysine is the most abundant early glycation product and fructosamine in vivo. Fructosamines are unstable products that slowly degrade to form AGE.

Fructosamines were traditionally considered to be a major source of AGE in vivo. Recently, however, as a result of advances in the methodology available for the precise chemical characterisation and quantification of pre-AGE and AGE (particularly liquid chromatography with tandem MS⁽Reference Ahmed and Thornalley³⁰⁾), it has became apparent that dicarbonyl-derived AGE are the predominant class of AGE in vivo ⁽Reference Thornalley, Battah, Ahmed, Karachalias, Agalou, Babaei-Jadidi and Dawnay²²⁾. Dicarbonyls are formed from the triosephosphates glyceraldehyde 3-phosphate and dihydroxyacetone phosphate (methylglyoxal), lipid peroxidation (glyoxal), fragmentation of early glycation products by the Namiki pathway⁽Reference Hayashi and Namiki³¹⁾ (glyoxal, 3-deoxyglucosone), oxidative degradation of nucleotides (glyoxal) and ketone body metabolism (methylglyoxal) and by enzymic degradation of fructosamines⁽Reference Delpierre, Rider, Collard, Stroobant, Vanstapel, Santos and Van Schaftingen^32, Reference Szwergold, Howell and Beisswenger³³⁾ (3-deoxyglucosone). In diabetes the triosephosphates are the most important source of dicarbonyls as a result of the previously described inhibitory effects of hyperglycaemia on GAPDH function. GAPDH activity has been shown to be the most important determinant of methylglyoxal concentration for a given glucose level (with an inverse correlation between GAPDH activity and methylglyoxal level)⁽Reference Beisswenger, Howell, Smith and Szwergold³⁴⁾. The products of sugar oxidation, methylglyoxal, glyoxal and 3-deoxyglucosone, react with mainly arginine residues of proteins and form AGE directly. Dicarbonyl-derived AGE on arginine residues, the hydroimidazolones (methylglyoxal-H, glyoxal-H, 3-deoxyglucosone-H), are the most abundant AGE in vivo in body fluids as well as in cellular protein (representing approximately 1% of the total arginine in some cell types)⁽Reference Thornalley, Battah, Ahmed, Karachalias, Agalou, Babaei-Jadidi and Dawnay²²⁾. The concentration of dicarbonyls as well as dicarbonyl-derived hydroimidazolones has been shown to be significantly increased in patients with diabetes (⩽3-fold for glycated plasma proteins, and ⩽10-fold for glycation-free adducts; see p. 65) compared with controls without diabetes⁽Reference Ahmed, Babaei-Jadidi, Howell, Beisswenger and Thornalley^35, Reference Ahmed, Babaei-Jadidi, Howell, Thornalley and Beisswenger³⁶⁾. The level of dicarbonyls correlates with glycaemia, and variations in postprandial glucose contribute substantially to the rise of dicarbonyls (and thus dicarbonyl-derived AGE), while levels of HbA_1c do not reflect the postprandial glucose fluctuations⁽Reference Beisswenger, Howell, O'Dell, Wood, Touchette and Szwergold³⁷⁾. Apart from the arginine-based dicarbonyl-derived AGE several other classes of AGE have been identified and chemically characterised (an overview of the current AGE classification based on their chemical structure and source is presented in Table 1).

Table 1. Current classification of advanced glycation end products (AGE)

3DG, 3-deoxyglucosone; FN, fructosamine; G, glyoxal; MG, methylglyoxal; AA, amino acid.

Enzymic defence against glycation

Although the formation of pre-AGE and AGE is a non-enzymic process, e.g. methylglyoxal arises by non-enzymic phosphate elimination from the two intermediates of glycolysis glyceraldehyde 3-phosphate and dihydroxyacetone phosphate (approximately 0·2–1% of the flux of triosephosphates under normoglycaemic conditions⁽Reference Phillips and Thornalley³⁸⁾), organisms including man have developed several enzymic detoxification systems to deal with those products⁽Reference Thornalley³⁹⁾, since high levels of methylglyoxal, for example, are highly cytotoxic. Surprisingly, the physiological role of dicarbonyls including methylglyoxal is still rather obscure (methylglyoxal is known to target several proteins involved in the regulation of cell growth, differentiation and cell death). From an evolutionary point of view monosaccharides such as glucose have evolved as a universal source of energy and C for metabolism; however, because of their intrinsically-high reactivity with amines, non-enzymic glycation is an unavoidable ‘background’ reaction in all living systems⁽Reference Szwergold⁴⁰⁾. Since uncontrolled glycation is detrimental to the function and integrity of biological macromolecules (the production of ROS from early glycation products, impairment of enzyme functions, perturbations of peptide hormone signalling, activation of AGE-specific receptors, cross-linking of structural proteins, impairment of protein recycling, mutagenicity etc.; see later) the need for regulatory systems capable of limiting and reversing such protein modifications has evolved in parallel⁽Reference Szwergold⁴⁰⁾. Passive regulatory mechanisms to limit unwanted excessive glycation include preference for monosaccharides with the lowest reactivity towards amines (i.e. glucose) and the maintenance of the lowest glycaemia possible or necessary as a result of prompt disposal of excess glucose to storage forms under insulin regulation. However, exclusively active mechanisms (deglycating enzyme systems) can (at least partly) maintain homeostasis when there are physiological or pathophysiological variations in the levels of glycating substrates. One of these detoxification mechanisms is the glyoxalase system⁽Reference Thornalley⁴¹⁾. Methylglyoxal reacts spontaneously with glutathione to form a hemithioacetal, which is converted into S-d-lactoyl-glutathione by glyoxalase I, and then further metabolised to d-lactate by glyoxalase II. The importance of methylglyoxal and its detoxification in hyperglycaemia has been confirmed experimentally; glyoxalase I overexpression in vitro completely protects against the hyperglycaemia-driven formation of methylglyoxal and AGE in bovine endothelial cells⁽Reference Shinohara, Thornalley, Giardino, Beisswenger, Thorpe, Onorato and Brownlee⁴²⁾. Similarly, fructoselysines may be enzymically degraded by fructosamine-3-kinase (FN3K)⁽Reference Delpierre, Rider, Collard, Stroobant, Vanstapel, Santos and Van Schaftingen^32, Reference Szwergold, Howell and Beisswenger³³⁾. FN3K phosphorylates fructoselysine residues on glycated proteins yielding fructosamine 3-phosphates, which are unstable and spontaneously decompose to form 3-deoxyglucosone. Based on current knowledge of both these enzymic systems (and several others such as aldehyde reductases and dehydrogenases and amadoriase) it is clear that deglycation plays a regulatory role under the normal metabolic conditions and efficacy of the systems may, consequently, play an important role in hyperglycaemia⁽Reference Conner, Beisswenger and Szwergold⁴³⁾. Whether the genetic variability in the glyoxalase and FN3K loci influence their efficacy will be discussed later (p. 68).

Biological effects of advanced glycation end products

AGE exert multiple biologically-important effects in living organisms by direct modification of proteins (and their functions) and indirectly via AGE-binding receptors. The importance of direct glycation certainly applies to long-lived proteins such as extracellular matrix proteins (e.g. collagen); their cross-linking (lysine to lysine or lysine to arginine residues), rigidity and resistance to proteolysis contribute to the changes in physical properties observed during aging, with accelerated rates in tissues (e.g. skin collagen) from patients with diabetes⁽Reference Yu, Thorpe and Jenkins⁴⁴⁾. If glycation occurs at specific sites it can also affect the cell–collagen interaction, e.g. modification of arginine within the RGD or GFOGER motifs recognised by integrins α1β2 and α2β1, which reduces cell interactions during turnover and platelet interactions and can ultimately affect tissue repair and wound healing in patients with diabetes⁽Reference Avery and Bailey⁴⁵⁾. Arginine-derived hydroimidazolone modification of integrin-binding sites of vascular-basement-membrane type IV collagen has been shown to induce endothelial cell detachment, anoikis and inhibition of angiogenesis, therefore possibly contributing to vascular damage in diabetes⁽Reference Dobler, Ahmed, Song, Eboigbodin and Thornalley⁴⁶⁾. In proteins with a faster turnover abnormal protein–protein or enzyme–substrate interactions can be affected by glycation. The most-abundant plasma protein in man, human serum albumin, is an important target of glycation in vivo. Peptide mapping of human serum albumin has identified hot spots for glycation by dicarbonyls (methylglyoxal) located in the drug-binding site and the active site of albumin-associated esterase activity⁽Reference Ahmed and Thornalley⁴⁷⁾; hot spots for modification by glucose have also been identified ⁽Reference Garlick and Mazer⁴⁸⁾. Similar hot spots for dicarbonyl-derived arginine-directed modification (in addition to glucose-derived lysine-directed modification) have been identified in Hb⁽Reference Gao and Wang⁴⁹⁾, both types of modifications have been shown to contribute to increased susceptibility to auto-oxidation, reduced α-helix content, increased thermolability and a weaker haem–globin linkage in glycated Hb⁽Reference Sen, Kar, Roy and Chakraborti⁵⁰⁾. These examples are just some of the glycated proteins studied; structural modification of many other proteins (such as apo, extracellular matrix proteins, crystalline etc.) also contributes to diabetic pathology. Another interesting effect of AGE has come from an in vitro study demonstrating that AGE dose-dependently impairs CD34+ progenitor cell function (i.e. incorporation of progenitor cells into the sprouting endothelium), which might be yet another pathophysiological factor (mediated by a hitherto unknown mechanism) of disturbed vascular function in diabetes⁽Reference Scheubel, Kahrstedt, Weber, Holtz, Friedrich, Borgermann, Silber and Simm⁵¹⁾.

Although most of the research has focused on the effect of AGE on proteins, it has become increasingly obvious that DNA serves as another target for AGE modification. The genotoxicity of AGE has been documented in vitro in several cell lines⁽Reference Stopper, Schinzel, Sebekova and Heidland^52, Reference Schupp, Schinzel, Heidland and Stopper⁵³⁾ and in vivo in patients with uraemia who are undergoing different types of haemodialysis⁽Reference Fragedaki, Nebel and Schupp⁵⁴⁾. DNA damage is induced by both the production of ROS via receptor-mediated signalling, probably involving the receptor for AGE (RAGE)/NAD(P)H oxidase pathway (estimated by 8-hydroxy-2-deoxyguanosine), and by the direct effect of AGE on DNA producing base modifications, stand breaks, photosensitisation and apurination or apyrimidination.

Circulating AGE-modified molecules also interact with specific cell-surface receptors on a range of cell types (in the circulation predominantly on monocytes and macrophages and endothelium). In some cases AGE undergo endocytosis and degradation, in others they activate intracellular signalling pathways and influence cellular phenotype. Several types of receptors for AGE-modified molecules have been identified: RAGE⁽Reference Neeper, Schmidt, Brett, Yan, Wang, Pan, Elliston, Stern and Shaw^55, Reference Schmidt, Vianna, Gerlach, Brett, Ryan, Kao, Esposito, Hegarty, Hurley and Clauss⁵⁶⁾; galectin-3⁽Reference Vlassara, Li, Imani, Wojciechowicz, Yang, Liu and Cerami⁵⁷⁾; OST-48; 80K-H⁽Reference Li, Mitsuhashi, Wojciechowicz, Shimizu, Li, Stitt, He, Banerjee and Vlassara⁵⁸⁾; scavenger receptors class A (I and II)⁽Reference Araki, Higashi, Mori, Shibayama, Kawabe, Kodama, Takahashi, Shichiri and Horiuchi⁵⁹⁾ and B (CD36 and BI); lectin-like oxidised LDL receptor-1; FEEL-1 and -2; probably others as yet unidentified⁽Reference Horiuchi, Sakamoto and Sakai⁶⁰⁾. RAGE, isolated and characterised in 1992⁽Reference Neeper, Schmidt, Brett, Yan, Wang, Pan, Elliston, Stern and Shaw^55, Reference Schmidt, Vianna, Gerlach, Brett, Ryan, Kao, Esposito, Hegarty, Hurley and Clauss⁶¹⁾, is an Ig-type cell-surface receptor that recognises the tertiary structure of multiple ligands including S100/calgranulins⁽Reference Hofmann, Drury and Fu⁶²⁾ and high-mobility-group box-1 protein⁽Reference Hori, Brett and Slattery⁶³⁾, amyloid β-peptides⁽Reference Yan, Chen and Fu⁶⁴⁾ and AGE. RAGE has similarities with signalling pattern-recognition receptors such as Toll-like or mannose-receptors that are expressed by immune cells and recognise proteins associated with microbial pathogens or cellular stress and participate predominantly in the innate immune response. Accumulating experimental data on RAGE functions and actions have been extensively reviewed throughout the past decade, particularly in the most recent comprehensive reviews⁽Reference Yan, Barile, D'Agati, Du Yan, Ramasamy and Schmidt⁶⁵–Reference Bierhaus, Stern and Nawroth⁶⁸⁾. Binding of AGE to RAGE has been shown to activate several intracellular signal transduction pathways (probably tissue- and cell-type-specific), mainly mitogen-activated protein kinases including extracellular regulated kinase 1/2, p38 mitogen-activated protein kinase and stress-activated protein kinase/c-Jun N-terminal kinase; furthermore, other pathways identified are the janus kinase/signal transducers and activators of transcription pathway, 1-phosphatidylinositol 3-kinase and NAD(P)H oxidase. As AGE–RAGE signalling is probably cell-type and ligand specific, the array of cellular and tissue responses has to be quite broad. One of the well-described down-stream events following activation of upstream kinases by AGE ligation to RAGE is NF-κB activation. Unlike the physiological transient NF-κB activation promoting cell survival under a variety of stimuli, in diabetes (in vivo in mononuclear cells from patients with T1DM as well as in vitro) NF-κB activation has been shown to be sustained over long-term periods as a result of overproduction of the NF-κB p65 subunit, while at the same time degradation of the inhibitory subunit of NF-κB is increased⁽Reference Bierhaus, Schiekofer and Schwaninger⁶⁹⁾. Considerable data relating to the actions of RAGE have been generated using blockade of signalling by soluble RAGE, transfection of cells with a dominant negative RAGE plasmid or transgenic mice expressing RAGE tissue-specifically or RAGE-deficient mice. Interestingly, RAGE also exists in vivo in a soluble form similar to other secreted pattern-recognition receptors (such as pentraxins, mannan-binding lectin etc.). There have been several independent descriptions of the existence of endogenous RAGE variants derived by alternative splicing of the gene leading to C- or N-terminal truncation⁽Reference Malherbe, Richards, Gaillard, Thompson, Diener, Schuler and Huber⁷⁰–Reference Yonekura, Yamamoto and Sakurai⁷²⁾. A proportion of the RAGE isoforms produced is tissue-specific, regulated by as yet unknown mechanisms. Circulating C-terminally-truncated soluble RAGE of approximately 50 kDa produced by endothelial cells is regarded as a naturally-occurring competitive inhibitor of signalling pathways induced by the transmembrane RAGE. Following the discovery of soluble RAGE, decreased levels have been demonstrated in several diseases in association with enhanced formation of AGE, such as coronary disease⁽Reference Falcone, Emanuele, D'Angelo, Buzzi, Belvito, Cuccia and Geroldi⁷³⁾, carotid and femoral atherosclerosis⁽Reference Koyama, Shoji and Yokoyama⁷⁴⁾, essential hypertension⁽Reference Geroldi, Falcone, Emanuele, D'Angelo, Calcagnino, Buzzi, Scioli and Fogari⁷⁵⁾, diabetic retinopathy⁽Reference Hayaishi-Okano, Yamasaki and Kajimoto^76, Reference Sakurai, Yamamoto and Tamei⁷⁷⁾, rheumatoid arthritis⁽Reference Pullerits, Bokarewa, Dahlberg and Tarkowski⁷⁸⁾ and Alzheimer's disease⁽Reference Emanuele, D'Angelo, Tomaino, Binetti, Ghidoni, Politi, Bernardi, Maletta, Bruni and Geroldi⁷⁹⁾.

Processing and metabolism of advanced glycation end products

The integrity of the cellular proteome is maintained by rapid proteolysis of misfolded or altered proteins by the proteasome⁽Reference Goldberg⁸⁰⁾. Proteasomes are large protein complexes that are located in the nucleus and cytoplasm of all eukaryotes. They can function as the 26S proteasome, which comprises one 20S core particle and two 19S regulatory caps that carry out ubiquitin- and ATP-dependent proteolysis, or as the 20S proteasome alone. Oxidised proteins are degraded directly by the 20S core particle without the involvement of the 19S regulatory cap and do not require ATP hydrolysis or tagging with ubiquitin⁽Reference Shringarpure, Grune, Mehlhase and Davies⁸¹⁾. Cellular proteins modified by AGE are also subject to intracellular proteolytic degradation, releasing free AGE into the circulation (i.e. AGE-free adducts)⁽Reference Thornalley, Battah, Ahmed, Karachalias, Agalou, Babaei-Jadidi and Dawnay²²⁾, and are probably the most important source of AGE in circulation, even if cellular glycated proteins exhibit some extent of resistance to proteasome degradation⁽Reference Bulteau, Verbeke, Petropoulos, Chaffotte and Friguet⁸²⁾. In vitro glyoxal treatment of fibroblasts inhibits 20S proteasome peptidase activities without changing the proteasome content⁽Reference Bulteau, Verbeke, Petropoulos, Chaffotte and Friguet⁸²⁾. Additionally, a decrease in proteasome degradation can be, to some extent, a result of AGE modification of lysine residues that are then inaccessible for ubiquitinylation or glycation by the proteasome itself⁽Reference Carrard, Dieu, Raes, Toussaint and Friguet^83, Reference Stolzing, Widmer, Jung, Voss and Grune⁸⁴⁾.

In the circulation the total pool of AGE consists of those bound to polypeptides (i.e. formed primarily on plasma proteins), peptides (probably released by extracellular proteolysis from tissue-immobilised AGE) and amino acids (formed by proteolytic degradation of intracellular proteins, direct modification of circulating amino acids and by exogenously-derived AGE, primarily those contained in food and absorbed from the intestine; see Fig. 1). The nomenclature of AGE in the context of their metabolism therefore distinguishes between (1) glycation adduct residues of proteins, (2) glycation adduct residues of peptides (0·5–12 kDa) and (3) glycation-free adducts (amino acids). The latter category represents the most abundant form of AGE in the plasma of healthy subjects as well as subjects with diabetes⁽Reference Ahmed, Babaei-Jadidi, Howell, Beisswenger and Thornalley³⁵⁾.

Fig. 1. Overview of advanced glycation end product (AGE) metabolism and factors influencing AGE turnover and the concentration of AGE in particular body compartments. MG, methylglyoxal; GLO I, glyoxalase I; FN3K, fructosamine 3 kinase; RAGE, receptor of AGE; ECM, extracellular matrix.

Role of the kidney in the excretion of advanced glycation end products

Renal clearance is the predominant means of excretion of AGE, particularly the low-molecular-weight fraction (glycation-free adducts)⁽Reference Ahmed, Babaei-Jadidi, Howell, Beisswenger and Thornalley³⁵⁾. The predominant plasma AGE (hydroimidazolones, N_ε-carboxymethyl-lysine (CML) and N_ε-carboxyethyl-lysine) have a high renal clearance⁽Reference Thornalley, Battah, Ahmed, Karachalias, Agalou, Babaei-Jadidi and Dawnay²²⁾ and their levels are inversely correlated with renal function⁽Reference Stam, Schalkwijk, van Guldener, ter Wee and Stehouwer⁸⁵⁾. AGE adducts and peptides are filtered into the glomeruli and a small proportion may be reabsorbed and degraded by proximal tubular cells⁽Reference Gugliucci and Bendayan⁸⁶⁾. Subjects with chronic renal failure have increased plasma levels of glycation-free adducts (fructoselysine, methylglyoxal-H, CML and N_ε-carboxyethyl-lysine) compared with normal controls (⩽5-fold); however, in patients with end-stage renal disease and renal replacement therapy plasma glycation free adducts are increased ⩽18-fold on peritoneal dialysis and ⩽40-fold on haemodialysis⁽Reference Agalou, Ahmed, Babaei-Jadidi, Dawnay and Thornalley⁸⁷⁾. AGE accumulate in patients with uraemia to a much greater extent than in subjects with normal renal function⁽Reference Odetti, Cosso, Pronzato, Dapino and Gurreri⁸⁸–Reference Sebekova, Podracka, Blazicek, Syrova, Heidland and Schinzel⁹¹⁾; however, AGE do not differ between patients with uraemia associated with diabetes and those with uraemia not associated with diabetes⁽Reference Miyata, Ueda, Shinzato, Iida, Tanaka, Kurokawa, van Ypersele de Strihou and Maeda^92, Reference Miyata, Fu, Kurokawa, van Ypersele de Strihou, Thorpe and Baynes⁹³⁾. Renal replacement therapy itself also plays a role; the concentration of AGE in the peritoneal dialysate exceeds that of the plasma, suggesting that AGE might be formed de novo in the peritoneal cavity from the glucose and its derivatives formed during heat sterilisation of the dialysate⁽Reference Thornalley²⁷⁾. The origin of increased AGE in uraemia is complex and not entirely dependent on their decreased renal clearance; it is more likely to be a consequence of enhanced oxidative and carbonyl stress and inflammation induced by uraemic toxins and contact with dialysis membranes and fluids⁽Reference Kalousova, Zima, Tesar, Stipek and Sulkova^94, Reference Miyata, van Ypersele de Strihou, Kurokawa and Baynes⁹⁵⁾.

The involvement of the liver in the removal of AGE has also been studied, as preliminary experimental data for animals injected with heavily-modified albumin indicate hepatic uptake by scavenger receptors and metabolism of AGE⁽Reference Smedsrod, Melkko, Araki, Sano and Horiuchi^96, Reference Hansen, Svistounov, Olsen, Nagai, Horiuchi and Smedsrod⁹⁷⁾. Similarly, elevation of AGE in subjects with liver cirrhosis and subsequent normalisation after liver transplantation has been demonstrated⁽Reference Sebekova, Kupcova, Schinzel and Heidland⁹⁸⁾. However, extraction of AGE formed in vivo (minimally modified compared with the previous experiments) from the blood entering and leaving the liver of both healthy subjects and patients with liver cirrhosis does not suggest marked hepatic degradation⁽Reference Ahmed, Thornalley, Luthen, Haussinger, Sebekova, Schinzel, Voelker and Heidland⁹⁹⁾.

Aetiology of chronic renal failure and end-stage renal disease, diabetic nephropathy

Diabetic nephropathy is a serious long-term consequence of diabetes that affects approximately 30% of patients with T1DM and T2DM, and it is the major single cause of chronic kidney disease and end-stage renal disease in developed countries (approximately 28%). Other diseases leading to chronic kidney disease and end-stage renal disease include hypertension (approximately 24%), glomerulonephritis (21%) and several less-common diseases such as polycystic kidney disease, chronic pyelonephritis, nephrolithiasis and systemic lupus erythematosus.

The aetiology of diabetic nephropathy comprises both the metabolic and haemodynamic changes that accompany diabetes⁽Reference Forbes, Fukami and Cooper¹⁰⁰⁾. The principal metabolic changes associated with hyperglycaemia have been described earlier (pp. 61–62). Haemodynamic changes are represented initially by increased intraglomerular pressure, which is independent of systemic blood pressure and can be detected quite early after the onset of the disease. Blockade of the rennin–angiotensin system (by angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) has been convincingly shown to delay the onset and progression of diabetic nephropathy, not only by its effect on filtration pressure but also by its non-haemodynamic effects (suppression of ROS production and cytokine release)⁽Reference Forbes, Fukami and Cooper¹⁰⁰–Reference Jacobsen¹⁰³⁾. All parts of nephron (the vasculature, glomerular filtration barrier, tubuli and also the kidney interticium) undergo pathological changes during the course of diabetic nephropathy. Experimental data (mainly from animal studies using inhibitors of advanced glycation) suggest that the pathogenic mechanism in the diabetic kidney is mainly mediated by AGE⁽Reference Thomas, Forbes and Cooper¹⁰⁴⁾. Direct modification of renal proteins by AGE may produce changes in charge selectivity, solubility, conformation (e.g. type IV collagen of glomerular basement membrane and its interaction with podocytes via integrins) and cell turnover (mesangium). Moreover, AGE also interact with specific receptors and binding proteins to influence the renal expression of growth factors and cytokines implicated in the progression of diabetic renal disease. Immunohistochemical data obtained from human or rodent kidneys show that RAGE is expressed by podocytes (but not in mesangial cells or glomerular endothelium)⁽Reference Tanji, Markowitz, Fu, Kislinger, Taguchi, Pischetsrieder, Stern, Schmidt and D‘Agati¹⁰⁵⁾ and by proximal tubular cells⁽Reference Oldfield, Bach, Forbes, Nikolic-Paterson, McRobert, Thallas, Atkins, Osicka, Jerums and Cooper¹⁰⁶⁾. In rodent models activation of RAGE contributes to glomerular pathology (enhanced permeability, inflammation and glomerular basement membrane thickening), mesangial expansion and tubular changes⁽Reference Oldfield, Bach, Forbes, Nikolic-Paterson, McRobert, Thallas, Atkins, Osicka, Jerums and Cooper¹⁰⁶–Reference Morcos, Sayed and Bierhaus¹¹⁰⁾. Engagement of RAGE by AGE (and probably also S100/calgranulins) in the diabetic kidney contributes through the cascade of signalling events using ROS as secondary messengers in the activation of transforming growth factor β, connective tissue growth factor and vascular endothelial growth factor axes directly responsible for renal remodelling. Experimental blockade of AGE formation by benfotiamine⁽Reference Babaei-Jadidi, Karachalias, Ahmed, Battah and Thornalley¹¹¹⁾, pyridoxamine⁽Reference Degenhardt, Alderson, Arrington, Beattie, Basgen, Steffes, Thorpe and Baynes¹¹²⁾ and alagebrium⁽Reference Forbes, Thallas, Thomas, Founds, Burns, Jerums and Cooper^113, Reference Thallas-Bonke, Lindschau, Rizkalla, Bach, Boner, Meier, Haller, Cooper and Forbes¹¹⁴⁾, blockade of RAGE by neutralising antibodies⁽Reference Flyvbjerg, Denner, Schrijvers, Tilton, Mogensen, Paludan and Rasch¹¹⁵⁾ or the absence of the latter in RAGE-knock-out mice⁽Reference Wendt, Tanji and Guo¹⁰⁷⁾ completely suppress structural and functional changes associated with diabetic nephropathy, thereby supporting the pathogenic role of AGE–RAGE interaction in diabetic nephropathy.

Maillard reaction; dietary advanced glycation end products sources

In 1912 the French scientist Louis Camille Maillard described the ‘browning’ or Maillard reaction between reducing sugars and amino acids during cooking⁽Reference Maillard¹¹⁶⁾. Products formed by this reaction (Maillard reaction products) contribute to the qualitative properties of foods such as colour, taste and aroma; moreover, it has become increasingly evident that they can also affect the nutritional and toxicological properties of food. The potential biological effect of endogenously-formed AGE, especially in situations like diabetes or uraemia, has also stimulated intensive interest in the potential contribution of dietary AGE to an individual's total AGE levels. Thermal processing of foods enhances their digestibility, sensory properties and shelf life, producing microbiologically-safe products with the desired nutritional quality that make a major contribution to the human diet. Although such treatment can lead to the formation of components with presumably health-promoting properties (such as antioxidants or melanoidins), it can also lead to the formation of potentially-harmful compounds (such as heterocyclic amines, acrylamide and Maillard reaction products)⁽Reference Somoza¹¹⁷⁾. It is clear that food is a rich source of pre-AGE (mainly fructoselysine) and AGE (mainly methylglyoxal-H, CML, pyrraline, pentosidine). Most dietary AGE are derived from sugar- and protein-rich cooked foods such as bakery products, roasted meat, milk and some other drinks (coke drinks, for example, have a lower AGE content than untreated milk, and the AGE content of milk further increases during pasteurisation and sterilisation⁽Reference Ahmed, Mirshekar-Syahkal, Kennish, Karachalias, Babaei-Jadidi and Thornalley¹¹⁸⁾), although, the levels depend also on the preparation conditions, presence of metals and water content⁽Reference Goldberg, Cai, Peppa, Dardaine, Baliga, Uribarri and Vlassara¹¹⁹⁾. Qualitative and quantitative assessment of AGE in food is currently an important area of food research⁽Reference Henle¹²⁰⁾.

Bioavailability, metabolic fate and excretion of dietary advanced glycation end products

It seems that highly-glycated proteins (containing fructoselysines and AGE) may not be digested efficiently (resistance to proteolysis) and that the majority of AGE present in foods are not absorbed from the gastrointestinal tract but excreted in the faeces. More precisely, approximately 10–30% of the ingested AGE are intestinally absorbed, mainly in the form of glycation-free adducts and peptides, and are subsequently found in the circulation⁽Reference Koschinsky, He, Mitsuhashi, Bucala, Liu, Buenting, Heitmann and Vlassara¹²¹–Reference Faist, Wenzel and Randel¹²³⁾, where the peptides undergo rapid degradation to free adducts, as shown by comparing the concentration of glycated peptides in the portal and systemic venous circulation⁽Reference Ahmed, Thornalley, Luthen, Haussinger, Sebekova, Schinzel, Voelker and Heidland⁹⁹⁾. Absorbed AGE are excreted rapidly in the urine by subjects or experimental animals with normal renal function, as indicated by balance studies quantifying recovery in the urine of CML, pyrraline and pentosidine from different foods or after injection of labelled compounds⁽Reference Faist, Wenzel and Randel¹²³–Reference Bergmann, Helling, Heichert, Scheunemann, Mading, Wittrisch, Johannsen and Henle¹²⁶⁾. In these studies ⩽80% of AGE were recovered in the urine, predominantly in the glycation-free adduct form, although it may have been as low as 2% in the case of protein-bound AGE (e.g. pentosidine in the free adducts in brewed coffee v. that of pretzel sticks). In animal studies faecal excretion was reported to be ⩽26–29% for CML but only 1–3% for fructoselysine⁽Reference Faist and Erbersdobler^122, Reference Faist, Wenzel and Randel¹²³⁾, which was considered to be an effect of the metabolisation of fructoselysine by colon microflora, e.g. Escherichia coli can degrade fructoselysine to glucose 6-phosphate and utilise it as a substrate⁽Reference Wiame, Delpierre, Collard and Van Schaftingen¹²⁷⁾. It is not clear whether AGE are similarly degraded by colon microflora⁽Reference Tuohy, Hinton, Davies, Crabbe, Gibson and Ames¹²⁸⁾.

It is difficult to interpret the findings of both animal and human studies of the bioactivity of AGE because of a series of confounding factors, experimental (study design, duration of administration, medical condition of subjects studied, species studied etc.) as well as methodological (different composition and preparation of high-AGE diet, analytical methods employed to quantify AGE etc.). While some studies have shown a significant effect of dietary AGE, other studies have not found such an effect (see following discussion). Nevertheless, such disparity certainly stimulates further carefully-designed experiments.

Bioactivity of dietary advanced glycation end products: animal studies

The biological effects of dietary AGE have been investigated in healthy rodents fed isoenergetic chow with different AGE contents (for study periods ranging from 6 weeks to 6 months). Rats on a high-AGE diet have been reported to show a higher increase in plasma AGE, urinary excretion of AGE, weight gain, renal protein excretion and renal expression of the pro-fibrotic cytokine transforming growth factor β⁽Reference Sebekova, Hofmann, Boor, Sebekova, Ulicna, Erbersdobler, Baynes, Thorpe, Heidland and Somoza¹²⁹⁾, while, increased fasting plasma insulin has been detected in mice⁽Reference Sandu, Song, Cai, Zheng, Uribarri and Vlassara¹³⁰⁾.

Similar findings have been obtained in studies of mice with diabetes (non-obese or db/db) fed a high-AGE diet (higher plasma AGE, weight gain and fasting plasma insulin)⁽Reference Hofmann, Dong, Li, Cai, Altomonte, Thung, Feng, Fisher and Vlassara¹³¹⁾, as well as in another study in which there was also progressive development of diabetic nephropathy (higher urinary AGE excretion, renal protein excretion, glomerular hypertrophy, mesangial expansion and expression of transforming growth factor β) and shorter survival (non-obese NOD mice)⁽Reference Zheng, He, Cai, Hattori, Steffes and Vlassara¹³²⁾. A low-AGE diet has also been found to delay the onset of diabetes in diabetic (NOD) mice⁽Reference Peppa, He, Hattori, McEvoy, Zheng and Vlassara¹³³⁾, improve wound healing in db/db mice⁽Reference Peppa, Brem, Ehrlich, Zhang, Cai, Li, Croitoru, Thung and Vlassara¹³⁴⁾ and delay the progression of atherosclerosis⁽Reference Lin, Reis, Dore, Lu, Ghodsi, Fallon, Fisher and Vlassara¹³⁵⁾. In the latter study genetically-hypercholesterolaemic (apoE-deficient) mice fed a low-AGE diet for 4 weeks following experimental injury of the femoral artery were reported to develop a lesser extent of neointimal formation (scar tissue) than animals fed a high-AGE diet⁽Reference Lin, Reis, Dore, Lu, Ghodsi, Fallon, Fisher and Vlassara¹³⁵⁾. Moreover, in the same animal model rendered diabetic by treatment with streptozotocin, 2-month dietary AGE restriction was associated with lower serum AGE, reduced formation of atheromatous lesions, lower tissue expression of AGE receptors and infiltration with inflammatory cells without concomitant differences in plasma glucose, TAG or cholesterol⁽Reference Lin, Choudhury, Cai, Lu, Fallon, Fisher and Vlassara¹³⁶⁾.

The effect of dietary AGE on renal function has been studied using an experimental model of renal failure (subtotally-nephrectomised rats). Nephrectomised rats were found to exhibit higher weight gain, proteinuria, kidney hypertrophy and expression of transforming growth factor β than healthy rats⁽Reference Sebekova, Hofmann, Boor, Sebekova, Ulicna, Erbersdobler, Baynes, Thorpe, Heidland and Somoza¹²⁹⁾. Administration of alagebrium (AGE breaker) was shown to delay and/or reverse established diabetic nephropathy in db/db mice by reducing systemic AGE and facilitating their urinary excretion⁽Reference Peppa, Brem, Cai, Zhang, Basgen, Li, Vlassara and Uribarri¹³⁷⁾. Of particular interest is a study designed to elucidate the potential effect of AGE as a secondary renal insult in rats with a developmental nephron deficit. A low-protein diet fed to female rats during pregnancy and lactation was found to reduce nephron number in their offspring compared with that of the offspring of female rats fed a normal-protein diet; however, no obvious differences were found in systemic blood pressure or glomerular filtration rate. Administration of AGE for 4 weeks beginning at the 20th week of age was shown to induce greater expression of the genes encoding transforming growth factor β and procollagen III as well as renal accumulation of AGE when compared with rats with a normal nephron status⁽Reference Zimanyi, Denton, Forbes, Thallas-Bonke, Thomas, Poon and Black¹³⁸⁾.

Bioactivity of dietary advanced glycation end products: human studies

In a study of ninety healthy subjects AGE intake (assessed by 3 d food records) was shown to be correlated with circulating AGE, AGE-modified LDL and high-sensitivity C-reactive protein (CRP) concentrations⁽Reference Uribarri, Cai, Sandu, Peppa, Goldberg and Vlassara¹³⁹⁾. In a larger study of 172 healthy subjects of different ages it was found that AGE are directly influenced by dietary intake (independent of age or energy intake), and circulating AGE (CML and methylglyoxal derivatives) are elevated in older subjects and correlated with indicators of inflammation and oxidative stress across all ages⁽Reference Uribarri, Cai, Peppa, Goodman, Ferrucci, Striker and Vlassara¹⁴⁰⁾. A 6-week nutritional intervention study of subjects with diabetes has demonstrated that circulating AGE can be modulated by altering dietary AGE intake, and high AGE intake is associated with higher levels of inflammatory molecules (CRP, TNFα) and markers of endothelial dysfunction (vascular-cell adhesion molecule 1)⁽Reference Vlassara, Cai, Crandall, Goldberg, Oberstein, Dardaine, Peppa and Rayfield¹⁴¹⁾. Furthermore, a comparison of the effects of low and high intakes of dietary AGE on the modification of plasma LDL in patients with diabetes who had equal glycaemic control and lipidaemia has shown that high AGE intake can transform circulating macromolecules to a much greater extent and render them more pro-atherogenic than those of subjects on a low AGE intake⁽Reference Cai, He, Zhu, Peppa, Lu, Uribarri and Vlassara¹⁴²⁾. Also, a high-AGE diet was found to induce more pronounced micro- and macrovascular dysfunction and endothelial dysfunction compared with a low-AGE diet in a cross-over study with twenty subjects with T2DM⁽Reference Negrean, Stirban and Stratmann¹⁴³⁾. The same effect (impaired flow-mediated macrovascular dilatation and endothelial dysfunction) was observed in a study in which forty-four subjects with T2DM and ten subjects without diabetes were administered a single oral AGE challenge⁽Reference Uribarri, Stirban, Sander, Cai, Negrean, Buenting, Koschinsky and Vlassara¹⁴⁴⁾.

When subjects with chronic renal insufficiency were assigned to either a high- or low-AGE diet the low intake was found to be associated with a decrease in AGE, CRP, plasminogen-activator inhibitor-1, vascular-cell adhesion molecule 1 and TNFα levels⁽Reference Peppa, Uribarri, Cai, Lu and Vlassara¹⁴⁵⁾. The importance of this finding is not clear, however, as a large cross-sectional study of >300 patients on haemodialysis that analysed the relationships between AGE and CRP and all-cause as well as cardiovascular mortality has shown better survival of subjects with high total serum fluorescent AGE and CML levels despite higher levels of inflammation markers (CRP)⁽Reference Schwedler, Metzger, Schinzel and Wanner¹⁴⁶⁾. The authors suggest that high serum AGE in patients on haemodialysis with better survival is either an epiphenomenon or reflects a better nutritional status. An inverse relationship between circulating AGE and glomerular filtration rate has also been reported for subjects with T1DM as well for subjects without diabetes⁽Reference Stam, Schalkwijk, van Guldener, ter Wee and Stehouwer^85, Reference Lieuw, van Hinsbergh, Teerlink, Barto, Twisk, Stehouwer and Schalkwijk¹⁴⁷⁾; however, a correlation with inflammatory markers was only present in subjects with diabetes. An even larger study that followed 450 subjects with T2DM and diabetic nephropathy for 2·6 years has ruled out serum CML level as an independent risk factor for cardiovascular or renal outcomes⁽Reference Busch, Franke, Wolf, Brandstadt, Ott, Gerth, Hunsicker and Stein¹⁴⁸⁾.

Interesting findings have been reported from a study of plasma AGE in vegetarians compared with subjects on a typical Western diet. Vegetarians were found to have unexpectedly higher plasma AGE, although not in association with typical AGE toxicity such as induction of insulin resistance (glycaemia), nephrotoxicity (glomerular filtration rate) or inflammation (CRP)⁽Reference Sebekova, Krajcoviova-Kudlackova, Schinzel, Faist, Klvanova and Heidland¹⁴⁹⁾. On further investigation of the components of the metabolic syndrome in vegetarians and omnivores⁽Reference Sebekova, Boor, Valachovicova, Blazicek, Parrak, Babinska, Heidland and Krajcovicova-Kudlackova¹⁵⁰⁾, the authors have proposed that this finding might be the result of a higher intake of fructose (in fruit), which is a better glycating agent that glucose, and that the potential AGE toxicity may be counterbalanced by higher levels of antioxidants often detected in vegetarians.